Apellis Pharmaceuticals to Discuss Q2 2025 Financial Results on July 31

Apellis Pharmaceuticals will host a conference call on July 31, 2025, to discuss its Q2 financial results. The company has introduced two approved medicines targeting C3 and launched the first-ever therapy for geographic atrophy. The ongoing belief in targeting C3 across various diseases suggests future growth and development opportunities for the company.

Apellis Pharmaceuticals Inc. (APLS, Financial) will host a conference call on July 31, 2025, to discuss its Q2 financial results. The company has introduced two approved medicines targeting C3 and launched the first-ever therapy for geographic atrophy, indicating potential future growth and development opportunities.

Baird analyst Colleen Kusy recently adjusted the price target for APLS, raising it from $47 to $50 while maintaining an Outperform rating [1]. This adjustment comes in anticipation of the company's Q2 earnings report. Additionally, a competitor's similar product is approaching approval for treating C3G, which was factored into the updated model for APLS.

Based on the one-year price targets offered by 19 analysts, the average target price for APLS is $35.53, with a high estimate of $60.00 and a low estimate of $18.00. The average target implies an upside of 77.28% from the current price of $20.04 [1]. The consensus recommendation from 22 brokerage firms is currently 2.2, indicating an Outperform status [1].

The company reported a 4% quarter-over-quarter growth in SYFOVRE injection demand, indicating strong market interest. EMPAVELI is advancing towards its second FDA approval with a priority review designation for C3G and IC-MPGN, with a PDUFA date set for July 28 [1]. SYFOVRE maintains over 60% market share and new patient starts exceeded 50% in Q1 [1].

However, SYFOVRE revenue fell short of expectations due to funding shortages at third-party co-pay assistance programs and a larger-than-expected inventory drawdown. The company faces ongoing challenges with co-pay assistance funding shortages, impacting commercial dose demand and increasing reliance on samples [1]. The company has not provided sales guidance for SYFOVRE, citing the need for a more steady state and the upcoming launch of EMPAVELI in new indications [1].

Annexon, Inc. reported complete enrollment in its Phase 3 ARCHER II trial for vonaprument, targeting dry AMD with topline data due in 2026 [2]. The trial design is global and randomized with a sham-controlled approach, aiming to assess various visual acuity and structural measures. Vonaprument has received Priority Medicine (PRIME) designation in Europe and Fast Track designation in the U.S., positioning it as a promising therapeutic candidate for dry AMD with geographic atrophy [2].

In summary, Apellis Pharmaceuticals is expected to report its Q2 financial results on July 31, 2025. The company's focus on C3 and geographic atrophy therapies, along with positive analyst ratings and market interest, suggests potential future growth and development opportunities.

References:
[1] https://www.gurufocus.com/news/2987223/apellis-apls-price-target-increased-by-baird-analyst-apls-stock-news
[2] https://www.nasdaq.com/articles/annexon-inc-completes-enrollment-phase-3-archer-ii-trial-vonaprument-targeting-vision